Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2001-01-19
2004-02-10
Weber, Jon P. (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C514S053000
Reexamination Certificate
active
06689741
ABSTRACT:
FIELD OF THE INVENTION
This invention pertains to new biocompatible polymers, a process for their preparation and compositions containing them.
BACKGROUND
Known in the prior art are polymer derivatives of dextrans obtained by substitution by carboxymethyl, carboxymethyl-benzylamide and carboxymethyl-benzylamide-sulfonate residues. These polymers, the process for their preparation and their properties, are described in French Patent No. 2,461,724 as well as in U.S. Pat. No. 4,740,594. Among these polymers, certain of them imitate the properties of heparin and can be used as plasma substitution products because of their anticoagulant and anticomplement properties. Others imitate a different property of heparin which consists of a stabilization, protection and potentiation of the in vitro biological activity of the growth factors of the FGF family (Tardieu et al., Journal of Cellular Physiology, 1992, 150, pages 194 to 203). Furthermore, French Patent No. 2,644,066 describes the use of carboxymethyl-benzylamide-sulfonate derivatives of dextran, referred to as CMDBS, alone or associated with FGFs, for cicatrization.
More recently, French Patent Nos. 2,718,023, 2,718,024 and 2,718,026 proposed the use of polymers capable of protecting, stabilizing and potentiating growth factors that have an affinity for heparin, such as the fibroblast growth factors or FGF and Transforming Growth Factor beta (TGF&bgr;), as a drug for the treatment of lesions of the gastrointestinal tract, nervous system and muscle tissues, respectively. To illustrate this protective effect of the CMBDS dextran derivatives, these patents present the results of the proteolytic digestion by trypsin of FGF1, FGF2 or TGF&bgr;. These properties of protection, stabilization and potentiation of the growth factors with an affinity for heparin enabled characterization of a new class of polymers, designated as HBGFPP to indicate “Heparin-Binding Growth Factor Protector and Potentiator”, that exhibit cicatrizing and repair activities in relation to muscle, nervous and gastrointestinal tract tissues, and which are devoid of anticoagulant activity at the doses employed.
In addition to the above HBGFPP applications, French Patent No. 2,718,025 proposes the use of these polymers as drugs for the treatment of inflammations. This anti-inflammatory activity is illustrated by the in vitro inhibitory action against proteolytic enzymes implicated in the inflammatory reaction such as leukocyte elastase or plasmin and in vivo by histological studies demonstrating a reduced inflammatory cellular reaction in tissues treated by CMDBS dextran derivatives.
However, these CMDBS dextran derivatives are compounds which are difficult to synthesize and present the risk of salting out residues that are known for their toxic effects such as benzylamine. Furthermore, the applications of the HBGFPP and thus of the CMDBS proposed in the prior art are limited solely to the repair and cicatrization of certain tissues.
SUMMARY OF THE INVENTION
The invention relates to a biocompatible polymer constituted by a sequence of identical or different components of the general formula (I): A
a
X
x
Y
y
, in which A represents a monomer, X represents a carboyxl group fixed on a monomer A, Y represents a sulfate or sulfonate group fixed on a monomer A; a represents the number of monomers A, x represents the substitution rate of the set of monomers A by the groups X, y represents the substitution rate of the set of monomers A by the groups Y. The invention also relates to the pharmaceutical or diagnostic compositions containing at least one polymer of general formula (I).
REFERENCES:
patent: 3762924 (1973-10-01), Morii et al.
patent: 4931553 (1990-06-01), Gill et al.
patent: 4935338 (1990-06-01), Masuda et al.
patent: 5314881 (1994-05-01), Rapisarda
patent: 25156 (1959-03-01), None
patent: 11 52 396 (1963-08-01), None
patent: 62514 (1967-04-01), None
patent: 62514 (1968-06-01), None
patent: 1572267 (1979-08-01), None
patent: 066283 (1982-12-01), None
patent: 450398 (1991-10-01), None
patent: 0 557 887 (1993-09-01), None
patent: 02231075 (1990-09-01), None
patent: 05313295 (1993-11-01), None
Baggi et al., “The Influence of Chondroitin Sulpuric Acid on the Scar Formation Process in Experimentally Produced Skin Wounds” (1970) Min. Chir., 25, 181-184 (with English Translation).*
Letourneur et al., “Antiproliferative capacity of synthetic detrans on smooth muscle cell growth: The model of derivatized dextrans as heparin-like polymers” (1993) J. Biomater. Sci., Polym. Ed., 4(5), 431-44.*
Letourneur et al., “In Vitro Stimulation Of Human Endothelial Cells By Derivatized Dextrans” (1993) In Vitro Cell. Dev. Biol.: Amin., 29A(1), 67-72.*
Ruechardt et al., “Pathological and Anatomical Findings After Administration of Dextran Sulfate and Carboxymethyl Dextran Sulfates in Experimental Animals” (1963) Acta Biol. Med. Ger., 10, 126-46.*
Gensicke et al., “Microdistribution of Radio Sulfur in Rabbits After Intravenous Injection of 35S-Labeled Dextran and Carboxymethyl Dextran Sulfates” (1965) Acta Biol. Med. Ger., 14(3-4), 409-16.*
Walton et al., “The Histochemical Basis Of Metachromasia” (1954) Brit. J. Exptl. Pathol., 35, 227-40.*
Alberts et al. “Molecular Biology of the Cell” (1983) Garland Publishing, Inc., New York, p. 703.*
Baggi et al., “Influence of Chondroitin Sulfate on the Process of Cicatrization of Experimentally Produced Cutaneous Injuries” (1970) Minerva Chirurgica, 25(3), 181-184, in MEDLINE, AN 71128533.*
Sasaki, S., “Production of Lymphocytosis by Polysaccharide Polysulfates (Heparinoids)” (1967) Nature, 214, pp. 1041-1042.*
Walton et al., “The Histochemical Basis of Metachromasia” (1954) Brit. J. Exptl. Pathol., 35, 225-240, in CAPLUS, AN 1954:78020.*
Poly(&bgr;-Malic Acid)Derivatives with Unsaturated Lateral Groups: Epoxidation as Model Reaction of the Double Bonds Reactivity,Marie-Agès Leboucher-Durand et al., Reactive & Functional Polymers, vol. 31, No. 1 (1996) 57-65.
New Investigations on Heparin-Like Derivatized Dextrans: CMDBS, Synergistic Role of Benzylamide and Sulfate Substituents in Anticoagulant Activity,O. Maiga-Revel et al., Carbohydrate Polymers, vol. 32, No. 2 (1997) 89-93.
Barritault Denis
Caruelle Jean-Pierre
Piper Rudnick LLP
Weber Jon P.
LandOfFree
Biocompatible polymers, process for their preparation and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biocompatible polymers, process for their preparation and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biocompatible polymers, process for their preparation and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3339734